(Nephrology) Office visit for a 42-year-old, established patient, to read tuberculin test results
For semaglutide, the predominant events were nausea, vomiting, diarrhea, off-label use, decreased appetite, weight loss, constipation, headache, hyperglycemia, and fatigue
For retatrutide, the form is unlikely to specifically ask about it, but it would fall under "investigational medications" or "clinical trial participation" if the form has such a category
Leerink joined at least five other firms whose analysts this past week responded to Lillys rising GLP-1 sales by boosting their price targets: B of A Securities (Geoff Meacham, PhD) Up 12.5%, from $1,000 to $1,125, and maintaining the firms Overweight rating
Hill NR, Fatoba ST, Oke JL, Hirst JA, OCallaghan CA, Lasserson DS, et al